Drugs / TAK 701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00831896 | Mar 2009 → Nov 2010 | cancer | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK 701 | “This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies.” NCT00831896 ↗ |
| Route | Intravenous | “Either 2, 5, 10, or 20 mg/kg IV” NCT00831896 ↗ |